MEDSNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
DataMeds AI, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$2.67+0.04 (+1.52%)
Close on Oct 19, 2026
- Market cap
- $6.87M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$21.33 (−88.88%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
DataMeds AI, Inc. saw revenue fall 78.2% to $8.02M over the twelve months to Jun 30, 2026.
Revenue
$8.02M
-78.2% vs. a year earlier
Operating income
-$70.26M
TTM Q2 2026
EPS, diluted
-$48.05
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.87M
- P/E ratio
- –
- Price to sales
- 0.86
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $8.02M
- Net income
- -$88.28M
- EPS, diluted
- -$48.05
- Book value per share
- -$7.58
- Diluted shares
- 3M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$8.02M-78.2% YoY
Gross profit
-$7.27M-345.0% YoY
Operating income
-$70.26M
Net income
-$88.28M
EPS, diluted
-$48.05
Reported periodTrailing twelve months